Latitude Pharma's Phospholipid Gel tech gains acceptance

With four new collaborative programs announced, San Diego-based Latitude Pharmaceuticals now has a total of eleven projects underway for its Phospholipid Gel (PG) Depot sustained release drug delivery technology. The parenteral drug delivery platform, for both small and large molecule therapeutics, can deliver up to seven days of low burst, peak-free sustained drug release following a subcutaneous or intramuscular injection. 

Says LPI President, Andrew Chen, PhD, “Our latest projects represent a growing recognition from startups to large pharma of the potential for PG Depot technology. We’re very pleased that our newest collaborators have selected (PG Depot) to overcome the short half-life and frequent injection issues problematic for many emerging medicines, especially proteins and peptides.”

- here’s Latitude's release

Suggested Articles

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.

Astex's oral reformulation of a common chemo combo looks to replace lengthy infusions with a once-daily tablet that patients can take at home.